Free · 13,591 studies indexed

lighttherapyresearch.com is a free index of research on photobiomodulation and light therapy, gathered from the world’s journals and trial registries.

Sections
Eye, Ear & Vision

Effectiveness of Low-Level Red Light in Controlling Myopia Progression in Children: A Systematic Review and Meta-Analysis

These findings suggest that LLRL therapy effectively reduces myopia progression in children, as indicated by improvements in SER, slower AL growth, and stabilization or slight increases in SFCT.

Excerpt from the paper’s abstract. Read the full paper for the details.

AI-generated summary

The authors conducted a systematic review and meta-analysis of 11 randomized controlled trials comparing low-level red light therapy with single-vision spectacles in children with myopia. They report that red light was associated with smaller increases in refraction and axial length at 3, 6 and 12 months. The authors note that further studies are needed to determine optimal dosage and long-term safety.

Studies included
11
Who or what was studied
Children and adolescents aged 16 years or younger with myopia
Limits stated in the abstract
The authors state that further studies are needed to determine optimal dosage, long-term safety, and overall efficacy.

Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.

Abstract

This study aimed to evaluate the effectiveness of low-level red light (LLRL) therapy compared to single-vision spectacles (SVS) in controlling myopia progression, focusing on spherical equivalent refraction (SER), axial length (AL), and subfoveal choroidal thickness (SFCT). A comprehensive search was conducted across PubMed, Cochrane Library, ScienceDirect, and Web of Science, including only randomized controlled trials (RCTs) involving myopic patients aged 16 years or younger. Mean differences were calculated with 95% CIs, and the I² statistic was used to assess heterogeneity among studies. The meta-analysis included 11 RCTs. At three months, significant differences were observed between LLRL and SVS in SER (estimate: 0.225; 95% CI: 0.042, 0.408; p = 0.016) and AL (estimate: -0.137; 95% CI: -0.280, 0.007; p = 0.062). At six months, significant differences were noted in SER (estimate: 0.450; 95% CI: 0.351, 0.550; p < 0.001), AL (estimate: -0.179; 95% CI: -0.278, -0.079; p < 0.001), and SFCT (estimate: 35.281; 95% CI: 23.230, 47.331; p < 0.001). By 12 months, the differences remained significant for SER (estimate: 0.806; 95% CI: 0.675, 0.937; p < 0.001) and AL (estimate: -0.294; 95% CI: -0.416, -0.172; p < 0.001). These findings suggest that LLRL therapy effectively reduces myopia progression in children, as indicated by improvements in SER, slower AL growth, and stabilization or slight increases in SFCT. However, further studies are necessary to determine the optimal dosage, long-term safety, and overall efficacy of LLRL therapy.

Abstract reproduced under the CC BY license. Source: PubMed, a service of the National Library of Medicine.

How to read a review: what to check before relying on this kind of research.

Terms in this paper: Myopia, Meta-analysis, Systematic review, Heterogeneity. Each links to its definition in the glossary.

A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.

Related studies